Visa Inc vs 22nd Century Group Inc — how do they compare? Visa Inc trades at $356.21 (market cap $685.71B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: Visa Inc is far larger — about 460208.1× 22nd Century Group Inc's market cap, and Visa Inc pays a 0.74% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| V | XXII | |
|---|---|---|
Market Cap | $685.71B | $1.49M |
Volume | 10,431,336 | — |
Sector | Financials | Technology |
52-Week High | $365.14 | $1.07K |
52-Week Low | $295.52 | $3.90 |
Enterprise Value | $696.30B | -$6.74M |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $355.82, down 0.76% on the day, with a bullish technical outlook supported by moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding the $3.10 estimate. Revenue growth remains robust, reaching $40B in 2025, and profitability is high with a net income margin of 51.68%. Recent news highlights Visa's focus on AI-driven commerce and stablecoin partnerships, positioning it for future payment innovations.
The stock offers a compelling long-term investment case with 85% analyst buy ratings and a $396.70 consensus price target, implying 11% upside. Key risks include competitive threats from fintech and regulatory pressures. Visa's strong cash flow and dividend payments provide shareholder value, but investors should monitor execution on AI initiatives and macroeconomic impacts on consumer spending.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →